glp-1 news november 6 2025 Weight-loss drugs such as Ozempic were in the headlines a lot in – and patent protections for these drugs expire in some countries in 2026. In this edition of #PeriodicGraphics in @ Societies take stand against off-brand

Benge explains

Mice overexpressing 11-HSD1 globally, or specifically in adipose tissue, have a metabolic syndrome phenotype of obesity, dyslipidemia, and glucose intolerance (28)

Clinical Trials & Approval The clinical development phase begins with Investigational New Drug (IND) submissions and proceeds through Phase I trials for safety and pharmacokinetics, Phase II for dose optimization and early efficacy, and Phase III for large-scale confirmation of therapeutic benefits

while the EULAR Points to Consider provide valuable guidance, the development of standardized criteria will be essential to advance research in this area

However, Hims & Herswhich reported revenue of $225mn from weight loss productsindicated that it intended to continue offering compounded semaglutide at doses not offered by Novo Nordisk in the United States

Improved metabolic health: Enhances insulin sensitivity and blood sugar regulation